(0.32%) 5 116.27 points
(0.31%) 38 358 points
(0.38%) 15 988 points
(-0.97%) $83.04
(5.36%) $2.03
(0.33%) $2 354.90
(0.54%) $27.68
(4.26%) $961.35
(-0.27%) $0.932
(-0.45%) $10.98
(-0.59%) $0.796
(1.63%) $93.37
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.21%
Live Chart Being Loaded With Signals
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States...
Stats | |
---|---|
本日の出来高 | 423 044 |
平均出来高 | 465 095 |
時価総額 | 103.80M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.150 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.78 |
ATR14 | $0.00800 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Junius Daniel M | Buy | 5 209 | Common Stock |
2024-03-29 | King Rachel K. | Buy | 3 334 | Common Stock |
2024-03-29 | Goldberg Mark Alan | Buy | 4 584 | Common Stock |
2024-01-12 | Johnson Bruce S | Buy | 250 000 | Employee Stock Option (right to buy) |
2024-01-12 | Semerjian Harout | Buy | 695 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
25.84 |
Last 98 transactions |
Buy: 7 229 799 | Sell: 5 299 394 |
ボリューム 相関
GlycoMimetics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
GlycoMimetics Inc 相関 - 通貨/商品
GlycoMimetics Inc 財務諸表
Annual | 2023 |
収益: | $10 000.00 |
総利益: | $-143 301 (-1 433.01 %) |
EPS: | $-0.580 |
FY | 2023 |
収益: | $10 000.00 |
総利益: | $-143 301 (-1 433.01 %) |
EPS: | $-0.580 |
FY | 2022 |
収益: | $74 925.00 |
総利益: | $-957 231 (-1 277.59 %) |
EPS: | $-1.780 |
FY | 2021 |
収益: | $1 160.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.230 |
Financial Reports:
No articles found.
GlycoMimetics Inc
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。